Familial adenomatous polyposis (FAP) is a rare condition that predisposes you (makes you more susceptible) to precancerous colorectal adenomatous polyps. Adenomatous polyps are abnormal growths that ...

Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of colorectal adenomas and, eventually, ...

Familial adenomatous polyposis (FAP) is caused by mutations in the APC gene and 2 different, or biallelic mutations, in the MUTYH gene. However, not all patients with colorectal polyposis are found to ...

Familial adenomatous polyposis (FAP) is an autosomal dominant disorder driven by germline mutations in the APC gene, leading to hundreds or thousands of colorectal adenomas and an almost inevitable ...

Familial adenomatous polyposis is caused by abnormalities in the APC gene. The Food and Drug Administration (FDA) has granted Fast Track designation to REC-4881 for the treatment of familial ...

The efficacy and safety of combination therapy with eflornithine and sulindac, as compared with either drug alone, in delaying disease progression in patients with familial adenomatous polyposis are ...

Urinary VEGF and MMP Levels As Predictive Markers of 1-Year Progression-Free Survival in Cancer Patients Treated With Radiation Therapy: A Longitudinal Study of Protein Kinetics Throughout Tumor ...

Tempest Therapeutics, Inc. has announced that the FDA has granted Orphan Drug Designation to its dual receptor inhibitor TPST-1495 for treating Familial Adenomatous Polyposis (FAP), a rare genetic ...

Purpose: Familial adenomatous polyposis is a phenotypically heterogeneous disease predisposing to colorectal cancer. It is dominantly transmitted, when associated with the APC gene, and recessively ...